...
首页> 外文期刊>Asia-Pacific journal of clinical oncology >Current mismatch repair deficiency tumor testing practices and capabilities: A survey of Australian pathology providers
【24h】

Current mismatch repair deficiency tumor testing practices and capabilities: A survey of Australian pathology providers

机译:目前的不匹配修复缺乏肿瘤测试实践和能力:澳大利亚病理提供者的调查

获取原文
获取原文并翻译 | 示例
           

摘要

Aim & Methods An electronic survey of the Royal College of Pathologists of Australasia accredited pathology services was conducted to assess Lynch syndrome tumor screening practices and to identify barriers and capabilities to screen newly diagnosed colorectal and endometrial tumors in Australia. Results Australia lacks a national policy for universal mismatch repair-deficient (dMMR) testing of incident colorectal and endometrial tumors cases. Routine Lynch syndrome tumor screening program for colorectal and/or endometrial tumors was applied by 95% (37/39) of laboratories. Tumor dMMR screening methods varied; MMR protein immunohistochemistry (IHC) alone was undertaken by 77% of 39 laboratories, 18% performed both IHC and microsatellite instability testing, 5% did not have the capacity to perform in-house testing. For colorectal tumors, 47% (17/36) reported following a universal approach without age limit, 30% (11/36) tested only "red flag" cases; 6% (3/36) on clinician request only. For endometrial tumors, 37% (12/33) reported clinician request generated testing, 27% (9/33) were screening only "red flag" cases, and 12% (4/33) carried out universal screening without an age criteria. BRAF V600E mutation testing of colorectal tumors demonstrating aberrant MLH1 protein expression by IHC was the most common secondary tumor test, with 53% of laboratories performing the test; 15% of laboratories also applied the BRAF V600E test to endometrial tumors with aberrant MLH1 expression despite no evidence for its utility. Tumor testing for MLH1 promoter methylation was performed by less than 15% laboratories. Conclusion Although use of tumor screening for evidence of dMMR is widely available, protocols for its use in Australia vary widely. This national survey provides a snapshot of the current availability and practice of tumor dMMR screening and identifies the need for a uniform national testing policy.
机译:AIM和方法对澳大利亚皇家病理学家皇家病理学家的电子调查进行了认可的病理学服务,以评估Lynch综合征肿瘤筛查实践,并识别筛选澳大利亚新诊断的结肠直肠癌和子宫内膜肿瘤的障碍和能力。结果澳大利亚缺乏国家失配维修 - 缺陷(DMMR)的国家政策对事件结直肠癌和子宫内膜肿瘤病例的案例。常规的Lynch综合征肿瘤肿瘤筛查程序用于结肠直肠和/或子宫内膜肿瘤的培训率为95%(37/39)实验室。肿瘤DMMR筛选方法变化;单独的MMR蛋白免疫组织化学(IHC)占39个实验室的77%,18%进行IHC和微卫星不稳定检测,5%没有能力进行内部测试。对于结直肠肿瘤,47%(17/36)在没有年龄限制的普遍方法下报告,30%(11/36)只测试了“红旗”病例;仅6%(3/36)临床请求。对于子宫内膜肿瘤,37%(12/33)报告临床医生要求生成测试,27%(9/33)仅筛选“红旗”病例,12%(4/33)在没有年龄标准的情况下进行通用筛查。 BRAF V600E对IHC的异步肿瘤的突变试验证明了IHC的异常MLH1蛋白表达是最常见的继发性肿瘤试验,具有53%的实验室进行测试; 15%的实验室还将BRAF V600E测试应用于具有异常MLH1表达的子宫内膜肿瘤,尽管其实用性没有证据。对MLH1启动子甲基化的肿瘤检测小于15%的实验室进行。结论虽然肿瘤筛查用于DMMR的证据,但广泛可用,但澳大利亚在澳大利亚的使用方案差异很大。本国家调查提供了肿瘤DMMR筛选的当前可用性和实践的快照,并确定了对统一的国家测试政策的需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号